检验医学与临床2026，Vol.23Issue(9)：1202-1208,7.DOI:10.3969/j.issn.1672-9455.2026.09.009
胸腺法新联合长效干扰素治疗NAs应答不佳的HBeAg阳性慢性乙型肝炎患者的临床疗效
The clinical efficacy of thymalfasin combined with long-acting interferon in the treatment of HBeAg-positive chronic hepatitis B patients with poor response to NAs
摘要
Abstract
Objective To explore the clinical efficacy of thymalfasin combined with long-acting interferon in the treatment of hepatitis B e antigen(HBeAg)-positive chronic hepatitis B(CHB)patients with poor re-sponse to nucleoside(acid)analogues(NAs).Methods From January 2022 to June 2024,124 patients with HBeAg-positive CHB who did not respond to NAs treatment for 24 weeks in the Third Hospital of Cangzhou City were selected as the research subjects.They were randomly divided into the observation group and the control group,with 62 cases in each group.The observation group was treated with thymalfasin for injection combined with pegylated interferon α-2b,while the control group was treated with pegylated interferon α-2b a-lone.Both groups were treated continuously for 48 weeks.The clinical efficacy,occurrence of adverse reactions and HBsAg seroconversion rate,HBeAg seroconversion rate,HBeAg conversion rate,HBV DNA seroconver-sion rate and peripheral blood T lymphocyte subsets and liver function indicators[alanine aminotransferase(ALT),aspartate aminotransferase(AST)]before and after treatment were compared.Results The total ef-fective rate of the observation group was higher than that of the control group(P＜0.05).The HBeAg sero-conversion rate,HBeAg conversion rate,and HBV DNA seroconversion rate of the observation group were higher than those of the control group,and the differences were statistically significant(P＜0.05).After treatment,the proportions of CD3+and CD4+T cells and the ratio of CD4+T cells/CD8+T cells in both groups were higher than those before treatment,and those in the observation group were higher than those in the con-trol group,with statistically significant differences(P＜0.05).The proportions of CD8+T cells in both groups were lower than those before treatment,and that in the observation group was lower than that in the control group,with statistically significant differences(P＜0.05).The levels of serum ALT and AST in both groups were lower than those before treatment,and those in the observation group were lower than those in the con-trol group,with statistically significant differences(P＜0.05).There were no statistically significant differ-ences in the incidence of fatigue,flu-like symptoms,digestive tract symptoms,etc.,among the two groups(P＞0.05).Conclusion Thymalfasin for injection combined with pegylated interferon α-2b in the treatment of HBeAg-positive CHB patients with poor response to NAs can effectively improve cellular immune function and liver function,and improve clinical efficacy.关键词
注射用胸腺法新/聚乙二醇干扰素α-2b/核苷(酸)类似物/应答不佳/乙型肝炎e抗原/慢性乙型肝炎Key words
thymalfasin for injection/pegylated interferon α-2b/nucleoside(acid)analogues/poor response/hepatitis B e antigen/chronic hepatitis B分类
医药卫生引用本文复制引用
张君,王晶,刘红,王晓玲..胸腺法新联合长效干扰素治疗NAs应答不佳的HBeAg阳性慢性乙型肝炎患者的临床疗效[J].检验医学与临床,2026,23(9):1202-1208,7.基金项目
河北省医学科学研究重点课题计划项目(20231128). （20231128）
